Healthcare entity
All 1 tracked stories fall under one category: acquisition. AstraZeneca is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Tagrisso, all published on August 2, 2026.
Last mentioned: Aug 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: acquisition. AstraZeneca is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Tagrisso, all published on August 2, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tagrisso. Shared-story counts are live from our verified record — not editorial picks.
A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
Tagrisso is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
